reCELL®

Restore pigmentation,
optimise outcomes
The ReCell® device is used to create a Regenerative Epithelial Suspension - RES™ - which can be used in conjunction with other treatments to restore pigmentation and improve the appearance of scars, sun-damaged skin, wrinkles and depigmented lesions associated with vitiligo and piebaldism. ReCell® has been safely used in thousands of procedures worldwide and offers distinct advantages.

**Restoration of Pigmentation**

- The multiple skin cell phenotypes present in RES™ allows for the appropriate interplay between the melanocytes and other cell types for normal pigmentation.\(^1\-^{10}\)
- Proven to achieve over 70% re-pigmentation in over 70% of patients.\(^3\)
- Viable melanocytes are successfully transplanted.\(^1\-^{10}\)

**Optimal Outcomes**

- Faster epithelialisation and the introduction of multiple skin cell phenotypes and skin regeneration factors mitigate against poor outcomes associated with delayed healing in older and health-compromised patients.\(^5\-^{11}\)
- Faster epithelialisation reduces ‘down time’ in aggressive ablative treatments.

**Commercial Benefits**

- Offers an exciting new revenue stream and the opportunity to expand clinic services to include hypopigmentation, vitiligo and piebaldism.
- Complementary to other treatments including laser, dermabrasion and medical needling to produce superior outcomes using existing capital equipment.
- A safe and rapid single-procedure treatment that does not require a costly laboratory.

**The regenerative mechanism is within the suspension...**

ReCell’s® unique proprietary technology enables a clinician to rapidly create RES™ – Regenerative Epithelial Suspension – using just a small sample of the patient’s skin.

- **Activated**, containing disaggregated cells that are no longer contact-inhibited, behaving like those at an acute wound’s edge. RES™ introduces the cell signaling associated with wound healing across the surface area of the wound.
- **Available** immediately within minutes and is non-cultured, meaning it can be produced and applied at point of care.
- **Autologous**, the patient is the donor, effectively eliminating rejection risks.
- **Complete**, containing the multiple skin cell phenotypes and normal wound healing factors that are necessary for the restoration of normal skin functionality and appearance.
EXAMPLE CASE: HYPOPIGMENTATION

There are limited options in treating hypopigmentation and vitiligo outside of a costly certified lab process or tedious mini and punch grafting.

In this case, RES™ was used to reintroduce healthy cells of each of the various phenotypes found in normal skin (including melanocytes), resulting in the restoration of normal pigmentation to a hypopigmented lesion associated with vitiligo.

Unlike other conventional therapies, treatment with RES™ is completed in a single procedure and does not require specialised equipment or a dedicated laboratory.

“Solid evidence that the melanocytes originating from the transplanted suspension really catch on, grow, and produce pigmentation in the depigmented spot.”

Dr. Albert Wolkerstorfer, Institute for Pigment Disorders, Amsterdam

Photos courtesy of L. Komen and A. Wolkerstorfer of the Netherlands Institute for Pigment Disorders.

EXAMPLE CASE: ACNE SCARRING

There are numerous methods available for the treatment of acne scarring. Hypopigmentation of the treated area is a risk, particularly with the treatment of individuals with darker skin tones. Severe scarring often requires deep ablation to minimise the textural imperfections, which further increases the risk of hypopigmentation and complications.

In this case, RES™ promoted faster epithelialisation to mitigate against scar formation following deep CO₂ laser ablation (to the mid reticular dermis). Additionally, the presence of the complete complement of skin cell phenotypes resulted in the restoration of normal pigmentation of the treated area and a uniform complexion.

“Healing times, especially in laser resurfacing could be reduced dramatically, so that both the risks of infection and scarring are drastically reduced.”

Dr. Gebhard Gramlich
Director Medical Department Private Clinic Hagenmuehle

Photos courtesy of Dr. Gebhard Gramlich
Clinical Summary

<table>
<thead>
<tr>
<th>TITLE</th>
<th>SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPIGMENTATION: Evaluation for performance of ReCell® for repigmentation.</td>
<td>RES™ + CO₂ laser with UVA within-subject pilot RCT (n=10) for patients with stable segmental vitiligo. Median re-pigmentation was 78% for RES™ treated areas, 0% for CO₂ control or no treatment areas.</td>
</tr>
<tr>
<td>REPIGMENTATION: Treatment of vitiligo lesions by ReCell® vs conventional melanocyte-keratinocyte transplantation (MKT): a pilot study.</td>
<td>Within-subject comparative study (n=5, MKT vs RES™). Comparable pigmentation was observed between RES™ and MKT, but without specialised laboratory facilities.</td>
</tr>
<tr>
<td>SCAR REVISION: Combination of Medical Needling and ReCell® for Repigmentation of Hypopigmented Burn Scars.</td>
<td>Patients with 1 year old hypopigmented scars treated with RES™ (n=20). The combination of medical needling and RES™ resulted in statistically significant objectively measured repigmentation vs within-subject control scar.</td>
</tr>
<tr>
<td>SCAR REVISION: Use of a novel autologous cell-harvesting device to promote epithelialization and enhance appropriate pigmentation in scar reconstruction.</td>
<td>RES™ treatment of post-traumatic scars (n=30) resulted in excellent or good aesthetic and functional outcomes (80%) and normal pigmentation (60%) of the patients.</td>
</tr>
</tbody>
</table>

How to Order

**ReCell® product number:**
ReCell®: C3RL01

To order please contact the appropriate regional sales office as indicated below.

**EUROPE:**
Tel: +44 (0) 1763 269 770
Fax: +44 (0) 1763 269 780
Email: cs.eu@avitamedical.com

**AMERICA:**
Tel: +1 818 356 9400
Fax: +1 818 356 9416
Email: cs.am@avitamedical.com

**ASIA-PACIFIC:**
Tel: +61 (0) 8 9474 7738
Fax: +61 (0) 8 9474 7742
Email: cs.ap@avitamedical.com

www.avita-regen.info


References: